RxDoctor Payments Data

Lauro Rocha, APRN

Adult Health · Newark, NJNPI 1639371628

Payments from drug & device makers

$2,012in general payments, 2019–2025

Across 83 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$939
  • Gilead$373
  • Janssen Products, LP$296
  • AbbVie$199
  • Johnson & Johnson$54
  • Boehringer Ingelheim$48
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$1,69884%
  • Education$31416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,012 in reported general payments places this provider in the 80th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$9,786
Medicare patients
38
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala54$114,283
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf31$72,522
OzempicSemaglutide67$65,300
SynjardyEmpagliflozin/Metformin Hcl81$59,333
MounjaroTirzepatide33$47,470
DovatoDolutegravir Sodium/Lamivudine12$35,907
TrulicityDulaglutide15$21,339
JardianceEmpagliflozin34$17,986
EntrestoSacubitril/Valsartan43$15,431
EliquisApixaban21$13,841
VascepaIcosapent Ethyl34$13,383
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl56$9,690
FarxigaDapagliflozin Propanediol11$9,194
Synjardy XrEmpagliflozin/Metformin Hcl24$8,575
ShingrixVaricella-Zoster Ge/As01b/Pf25$5,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$373$114,28354 claims
Boehringer IngelheimSynjardy, Jardiance, Synjardy Xr$48$85,895139 claims
Janssen Products, LPSymtuza$296$72,52231 claims
Lilly USA, LLCMounjaro, Trulicity$26$68,80948 claims
Viiv Healthcare CompanyDovato$939$35,90712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →